. The first cycle was trace labeled with 111 In for biodistribution assessment using γ camera imaging. Subsequent cycles were administered every 3 weeks up to a maximum of six cycles, depending on toxicity and response. Pharmacokinetic analysis was based on radioassay and ELISA. Results: Nine patients were enrolled in the study. Biodistribution images showed initial blood pool activity, followed by markedly increased hepatic uptake by day 2, and fast blood clearance in all patients. There was low uptake in tumor in all patients. The overall T½β of 111 In-CMD-193 was 102.88 ± 35.67 hours, with no statistically significant difference between the two dose levels. One patient had a partial metabolic response on 18 F-fluorodeoxyglucose-positron emission tomography ( 18 F-FDG PET) after four cycles, but no radiological responses were observed. Myelosuppression and effects on liver function were the most significant adverse effects.
Conclusions: CMD-193 shows rapid blood clearance and increased hepatic uptake compared with prior studies of the parental antibody hu3S193. These results highlight the importance of biodistribution and pharmacodynamic assessment in early phase studies of new biologics to assist in clinical development. ( The concept of antibody-targeted chemotherapy was successfully translated into the clinic in 2000, when gemtuzumab ozogamicin (Mylotarg, also known as CMA-676) was approved by the Food and Drug Administration for relapsed acute myeloid leukemia (1) . This CD33-targeted immunoconjugate of calicheamicin has accelerated the investigation of this therapeutic strategy in solid tumors. CMD-193 is one such calicheamicin immunoconjugate that makes use of the same drug-linker combination as that used in Mylotarg, but the antibody to which it is conjugated targets the Lewis Y (Le y ) antigen. Le y (CD174) is a difucosylated tetrasaccharide internalized antigen displayed on both glycolipid and glycoprotein backbones of membrane surface molecules, and is involved in cellular motility and adhesion (2) . Le y has restricted normal tissue expression, and is overexpressed in the majority of epithelial carcinomas (40-90%) including breast, ovary, pancreas, prostate, colon, and lung cancers (3) (4) (5) (6) (7) (8) (9) (10) (11) .
The immunoconjugate CMD-193 is composed of G193, a humanized monoclonal antibody based on the anti-Le y antibody hu3S193 (12) , covalently linked to NAc-γ calicheamicin DMH via an acid-labile AcBut linker with retention of Le y affinity. In prior phase I trials, hu3S193 showed specific targeting of Le y -expressing tumors, restricted normal tissue distribution, a long serum half-life, and lack of immunogenicity (13, 14) . Hu3S193 is currently under development in phase II trials as a naked humanized antibody in Le y -expressing tumors. Dosedependent regression of Le y -expressing human carcinoma xenografts by the immunoconjugate CMD-193 has been shown in preclinical studies, highlighting the potential therapeutic potential of CMD-193 in cancer patients (15) . Initial clinical development of CMD-193 involved a dose escalation phase I study in patients with Le y -expressing advanced solid tumors with an expanded preliminary evaluation of efficacy in patients with nonsmall cell lung carcinoma.
In support of the initial clinical development of CMD-193, we conducted an additional phase I dose escalation study of CMD-193 in patients with advanced solid tumors expressing the Le y antigen. The primary objectives of this trial were to determine the biodistribution and pharmacokinetics of 111 In-CMD-193. The tumor uptake of 111 In-CMD-193 was based on qualitative and quantitative assessment of biodistribution images and dosimetry. Secondary objectives were to determine tumor response to CMD-193 through changes in tumor 18 F-FDG PET metabolism and measurement by Response Evaluation Criteria in Solid Tumors (RECIST) criteria (16) .
Materials and Methods
Patients. Eligible patients were >18 y of age, who had histologically confirmed solid malignancies with ≥20% tumor cells displaying Le y antigen positivity on immunohistochemistry of archived tumor samples (13) , and who had progressed following standard therapy. Inclusion criteria included the following: measurable disease, Eastern Cooperative Oncology Group performance status of 0 to 1, and adequate renal, hepatic, and bone marrow function and ability to give informed consent. Exclusion criteria included the following: cancer therapy within 21 111 In-(MDS Nordion) via the bifunctional metal ion chelate CHX-A″-diethylenetriaminepentaacetic acid according to methods described previously (12, 17) .
Assessments. Biodistribution evaluation was done by whole body γ camera scans on day 1, day 2, day 3 or 4, day 5 or 6, and day 7 or 8 following 111 In-CMD-193 infusion. Pharmacokinetic sampling of 111 In-CMD-193 was done during cycle 1 on day 1 (preinfusion, 1 and 4 h postinfusion commencement), day 3, day 8, and day 15. Changes in tumor metabolism were evaluated using 18 F-FDG-PET, which was done at screening, between days 15 and 21 of cycles 2 and 4, and at study completion. Antitumor response was assessed using RECIST criteria (16) , with computed tomography (CT) scans performed at screening, between days 15 and 21 of cycles 2 and 4, and at study completion. Safety evaluation was done weekly throughout the trial with all adverse events documented and graded according to National Cancer Institute Common Terminology Criteria for Adverse Events version 3.0. Causality was determined as "related to study drug" if the event was deemed definitely, probably, or possibly related to the administration of CMD-193 by the investigator.
Biodistribution and whole body clearance. Whole body planar γ camera images were acquired on a dual-headed γ camera (Picker International and Phillips Medical Systems). Single photon emission CT (SPECT) images of a region of the body with known tumor were also obtained on at least one occasion during this period. Biodistribution analysis was done by examination of whole body and SPECT images by experienced nuclear medicine physicians. Comparison to prior studies of parental antibody hu3S193 was also done (13) . Whole body and organ clearance of 111 In-CMD-193 was calculated from quantitative whole body conjugate view γ camera images obtained at the multiple time points postinfusion using a well-validated method (13, 18, 19) .
Pharmacokinetics. Serum obtained from patients following infusion of 111 In-CMD-193 was aliquoted and counted in a γ scintillation counter (Packard Instruments). The results were expressed as % injected dose per liter (%ID/L) and μg/mL. Estimates were determined for the following parameters: T½α and T½β (half-lives of the initial and terminal phases of disposition); V1, volume of central compartment; C max , maximum serum concentration; AUC, area under the serum concentration curve extrapolated to infinite time; and CL, total serum clearance. A two-compartment i.v. bolus model with macroparameters, no lag time, and first-order elimination (WNL Model 8) was fitted to individual serum 111 In-CMD-193 data for each subject using unweighted nonlinear, least squares with WinNonLin version 5.2 (Pharsight Corp).
Translational Relevance
Measured serum levels of CMD-193 were expressed as ng/mL. Serum samples were also obtained for measurement of total and free calicheamicin by a validated ELISA protocols (LLOQ, 2.45 ng/mL).
Tumor metabolic response assessment. Patient preparation for and acquisition of FDG-PET scans were standardized (20, 21) . For each FDG-PET performed, the maximum standardized uptake value (SUV max ) corrected for body weight for all target lesions >2cm identified on CT imaging was calculated using region of interest. The region of interest was determined with the aid of the anatomic detail provided by the CT scan. SUV max for normal lung tissue was taken as the reference region for each patient, which ensured that any SUV changes in tumors could be directly attributed to treatment response or to disease progression (16) . Metabolic response was calculated using the target lesion with the greatest baseline SUV max , and was categorized according to the European Organization for Research and Treatment of Cancer guidelines (20) .
Human-anti-human antibody response. Assay of serum for anti-CMD-193 antibodies in human serum was done by Wyeth Pharmaceuticals using a validated ELISA protocol.
Statistical considerations. The independent samples t test was used to compare mean pharmacokinetic and clearance parameters across the two dose cohorts of CMD-193. It was also used to compare results with those obtained with our prior phase I trial using the unconjugated parental antibody hu3S193 (13) .
Results
Patient characteristics. Nine patients were eligible and enrolled (six patients, 1.0 mg/m 2 cohort; three patients, 2.6 mg/m 2 cohort). Baseline patient demographics and disease characteristics are shown in In-CMD-93 showed rapid clearing of blood pool activity, followed by markedly increased hepatic uptake by day 2, persisting to day 8 ( Fig. 1 ). This pattern was observed for all patients in both dose levels. No significant uptake of 111 In-CMD-193 in tumor was visualized in target lesions for all patients.
Whole body clearance was (mean ± SD) 47.82 ± 3.24 hours, and there was no statistically significant difference between dose levels (P = 0.74). Quantitative analysis confirmed the high levels of hepatic uptake of 111 In-CMD-193 apparent visually on biodistribution images. Compared with the parental hu3S193 antibody, hepatic uptake was significantly higher at 24 hours (time of maximal hepatic uptake; Table 2 ). Tumor uptake was also significantly lower for CMD-193 compared with hu3S193 (Table 2) .
Pharmacokinetics and HAHA. CMD-193 displayed a fast clearance from blood, consistent with the biodistribution findings (Table 3 ). Selected serum samples from patients were analyzed by fast protein liquid chromatography for immune complex or metabolite formation, and no complexes or metabolites or free 111 In-chelate was observed up to 72 hours postinfusion (data not shown). No significant differences were found for T½α, T½β, clearance, or V1 between the two dose levels. The results for CMD-193 were significantly different compared with the parental antibody hu3S193 (13), with T½β for CMD-193 102.88 ± 35.67 hours versus 189.63 ± 62.17 hours for hu3S193 (P < 0.001) and CL for CMD-193 113.22 ± 56.58 mL/h versus 22.09 ± 9.87 mL/h for hu3S193, P < 0.001. No HAHA was detected in any patient. Free calicheamicin levels were at or below the limit of assay quantitation in all patients.
Response assessment. Metabolic response by FDG-PET and antitumor response according to RECIST criteria results are shown in Table 1 . Response could not be formally measured in patient 161, who died of rapid progressive disease following early study withdrawal during cycle 2. Patient 103 showed a partial metabolic response (PMR), with a 41.7% reduction in SUV max (prestudy, 10.8; restaging, 6.3) after four cycles of CMD-193 (Fig. 2) . This was despite no change in CT dimensions of the target lesion. Stable metabolic disease (SMD) was observed in three patients and four had progressive metabolic disease (PMD) at end of study assessment. Patient 108 showed SMD, but had a 25% reduction in SUV max (prestudy, 4.4; restaging, 3.3) after five cycles of treatment. Of the four patients with PMD, three were in dose cohort 1 and one was in dose cohort 2. Assessment of antitumor response by CT scanning showed four patients with stable disease (SD) and four with progressive disease (PD) at final staging. Adverse events. CMD-193 at doses of 1.0 and 2.6 mg/m 2 was reasonably well tolerated, and no difference in toxicity was observed between patients in the two dose levels (Table 4) .
Four patients, two from each dose cohort, were withdrawn because of toxicity. The main adverse events with some relationship to CMD-193 were asymptomatic myelosuppression, particularly thrombocytopenia (12 grade 1-2 events, 2 grade 3 events, and 1 grade 4 event), and abnormal liver function (5 grade 3 events). All other related adverse events, including fatigue, lethargy, anorexia, and nausea, were mild (grade 1-2). There were no infusion-related reactions. There were no serious adverse events related to study drug, and no serious or severe In-CMD-193, there was initial blood pooling, followed by markedly increased hepatic uptake by day 2 that persisted to day 8. No tumor uptake was apparent in the whole body γ camera images (arrow) or SPECT (D). E, corresponding CT scan shows the large hepatic metastasis, also evident in F, coregistered SPECT/CT scan. 
Discussion
This study showed lack of targeting of CMD-193 to known sites of metastatic disease, and marked hepatic uptake and rapid clearance from blood, consistent with the observed short T 1/2 β and fast serum clearance. There were no documented objective responses seen in size of tumor, but one patient did display a PMR according to 18 F-FDG-PET analysis. These bioimaging and pharmacokinetic results highlight the importance of detailed investigation of the properties of antibodies and immunoconjugates in early phase I trials, and can provide critical information impacting on subsequent clinical development.
The biodistribution, clearance, and pharmacokinetic properties of CMD-193 were found to be significantly different to the parental antibody hu3S193. Phase I studies of 111 In-hu3S193 have shown prominent specific uptake in tumor, a lack of consistent normal tissue/organ uptake, and a long half-life in blood (13, 14) . This is in contrast to the fast clearance from blood, rapid uptake in liver parenchyma, and lack of tumor uptake of 111 In-CMD-193 observed in this study. Importantly, one patient (patient 103) participated in both clinical studies, allowing direct comparison of biodistribution, clearance, and hepatic uptake between CMD-193 and hu3S193 in the same patient (Fig. 3) . The whole body clearance and terminal half-life of 111 In-CMD-193 were also faster than that observed with other humanized IgG1 antibodies (19, 22) . Interestingly, this difference in serum clearance of a toxin-conjugate, compared with the parental antibody (hu3S193), has also been recently reported for the Herceptin-maytansinoid conjugate T-DM1, which had a T½ of 2.1 to 3.7 days (compared with Herceptin T½ of >10 days), although biodistribution data were not reported for this conjugate (23, 24) .
The rapid clearance of CMD-193 from blood, and the liver uptake observed, was not predicted by preclinical studies. The marked difference in biodistribution of CMD-193 compared with parental antibody hu3S193 cannot be explained by antibody specificity, as retention of Le y binding by CMD-193 was confirmed before infusion. The lack of CMD-193 complexes or metabolites in blood (measured by fast protein liquid chromatography), absence of HAHA, and the lack of prominent spleen or bone marrow uptake on imaging, excludes CMD-193 complexes or free 111 In-contributing to the increased liver uptake. It is possible that a physicochemical change induced by conjugation of the antibody with calicheamicin may have led to the altered biodistribution observed in this study. Size and charge are known to influence the uptake of circulating macromolecules by hepatic cells, possibly by influencing electrostatic attraction and hydrophobic interactions or specific receptormediated interactions with scavenger receptors, which remove acidic macromolecules (24) (25) (26) . Despite the low uptake of CMD-193 in tumor, the observation of a PMR in one patient highlights the potent biological effect of calicheamicin, even at low tumor concentrations. To our knowledge, CMB-401 (hCTM01-calicheamicin) is the only calicheamicin immunoconjugate to have reached phase II trials in solid tumors. This combined N-acetyl/analogue of calicheamicin with a polymorphic epithelial mucin targeting humanized antibody hCTM01 using an amide-based linkage. An initial phase I study in patients with epithelial ovarian cancer, which included a predose of unconjugated antibody to minimize uptake in normal tissues and complex formation with circulating antigen, found it to be tolerable and defined the maximum tolerated dose (27) . A subsequent phase II trial in 21 patients with recurrent ovarian cancer failed to show clinical efficacy (28) . In this case, a lack of efficacy (and suspension of development) was attributed to instability of the amide linker, although free calicheamicin and measurement Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase. In-hu3S193 observed in the prior phase I study 13 . of serum complex formation results were not published. Biodistribution and pharmacokinetic assessment of CMB-401 in patients were also not done in this trial, and hence, it is not possible to draw direct comparisons with CMD-193 other than the common toxicity profile relating to calicheamicin (29, 30) .
CMD-193 showed a similar toxicity profile to Mylotarg and CMB-401, with predominant hepatic and hematological toxicity. Hepatic toxicity seen in some patients following administration of CMD-193 may be explained by hepatic uptake and metabolism of the NAc-γ calicheamicin DMH, as Le y is not expressed by liver cells (4) . With Mylotarg however, hepatotoxicity can be explained partly by sinusoidal obstruction syndrome, the mechanism of which probably involves targeting of CD33 + cells in the sinusoids of the liver (30) . Although liver toxicity was also documented in phase I study of CMB-401 (but interestingly not mentioned in phase II trial), in this case, it was attributed to expression of target antigen in liver bile duct cells, rather than to uptake of calicheamicin metabolites by hepatocytes (27, 28) . Myelosuppression following CMD-193 may be explained by the myelosuppressive effects of a small amount of free calicheamicin.
In summary, the detailed biodistribution and pharmacokinetic assessment performed in this trial was able to identify an unexpected in vivo fate for the novel Le y -targeting immunoconjugate CMD-193 in patients with advanced Le y -positive epithelial cancers. Although CMD-193 was generally tolerable, and hints of biological activity were shown, the marked hepatic uptake, low tumor uptake, and rapid blood clearance observed was in contrast to the parental antibody hu3S193. On the basis of clinical trial data and the biodistribution results shown in this study, the clinical development of CMD-193 has not been continued. These results highlight the importance of detailed biodistribution and pharmacodynamic assessment in early phase studies of new biologics to inform and guide clinical development.
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